For the quarter ending 2026-03-31, IR had $25,600K increase in cash & cash equivalents over the period. $163,400K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 193,800 | 268,400 | 469,200 | 72,700 |
| Amortization of intangible assets | 107,500 | 109,700 | 94,900 | 91,600 |
| Depreciation | 29,400 | 31,100 | 29,600 | 28,900 |
| Impairment of goodwill and other intangible assets | - | 7,600 | 0 | 265,800 |
| Non-cash restructuring charges | - | 0 | 0 | - |
| Stock-based compensation expense | 15,900 | 7,200 | 14,900 | 16,700 |
| Loss on equity method investments | 0 | 0 | 0 | -120,900 |
| Foreign currency transaction losses, net | -2,200 | -3,000 | -2,800 | -6,000 |
| Non-cash adjustments to carrying value of lifo inventories | 5,400 | 2,300 | 5,200 | 7,300 |
| Loss on extinguishment of debt | - | 0 | 0 | 0 |
| Loss on sale of asbestos-related assets and liabilities | - | 0 | 0 | 0 |
| Deferred income taxes | - | -79,400 | - | - |
| Other non-cash adjustments | -1,000 | -2,700 | -2,400 | -2,400 |
| Receivables | -59,700 | 82,400 | 15,000 | -13,000 |
| Inventories | 74,700 | -83,500 | 23,600 | 31,900 |
| Accounts payable | -133,500 | 147,900 | -25,000 | 26,200 |
| Accrued liabilities | 16,000 | -38,600 | 53,900 | -90,300 |
| Other assets and liabilities, net | 23,000 | -36,000 | 31,300 | 97,100 |
| Net cash provided by operating activities | 199,700 | 499,000 | 758,600 | 550,600 |
| Capital expenditures | 36,300 | 37,500 | 29,100 | 35,300 |
| Net cash paid in acquisitions | 52,000 | 65,200 | 249,400 | 47,000 |
| Proceeds from disposals of property, plant and equipment | 3,900 | 0 | 0 | - |
| Other investing | - | 0 | 0 | 0 |
| Net cash used in investing activities | -84,400 | -102,700 | -317,200 | -2,784,700 |
| Principal payments on long-term debt | - | 0 | 0 | 0 |
| Proceeds from long-term debt | - | 0 | 0 | 0 |
| Purchases of treasury stock | 89,500 | 314,700 | 193,100 | 500,200 |
| Cash dividends on common shares | 7,800 | 7,800 | 7,900 | 8,000 |
| Proceeds from stock option exercises | 15,900 | 2,500 | 3,700 | 3,900 |
| Payments to settle cross-currency swaps | - | 0 | 0 | 0 |
| Payments of deferred and contingent acquisition consideration | 1,400 | 1,800 | 3,400 | 1,400 |
| Payments of debt issuance costs | - | 0 | 0 | 0 |
| Other financing | -1,000 | -5,400 | -2,800 | -7,400 |
| Net cash used in financing activities | -83,800 | -327,200 | -203,500 | -513,100 |
| Effect of exchange rate changes on cash and cash equivalents | -5,900 | 3,100 | -6,600 | 47,500 |
| Net increase in cash and cash equivalents | 25,600 | 72,200 | -134,000 | -302,200 |
| Cash and cash equivalents, beginning of period | 1,248,800 | 1,176,600 | 1,310,600 | 1,612,800 |
| Cash and cash equivalents, end of period | 1,274,400 | 1,248,800 | 1,176,600 | 1,310,600 |
Ingersoll Rand Inc. (IR)
Ingersoll Rand Inc. (IR)